U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C34H32N4O9
Molecular Weight 640.6393
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOMOL

SMILES

OC1C(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)CCCC1(COC(=O)C4=CN=CC=C4)COC(=O)C5=CN=CC=C5

InChI

InChIKey=VRAHPESAMYMDQI-UHFFFAOYSA-N
InChI=1S/C34H32N4O9/c39-28(24-6-1-12-35-16-24)44-20-33(21-45-29(40)25-7-2-13-36-17-25)10-5-11-34(32(33)43,22-46-30(41)26-8-3-14-37-18-26)23-47-31(42)27-9-4-15-38-19-27/h1-4,6-9,12-19,32,43H,5,10-11,20-23H2

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01291

Hypolipidemic agent, Nicomol is an ingredient of Cholexamin in Japan. Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched by KYORIN Pharmaceutical in 1971. It is indicated for the treatment of hyperlipemia, improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome.

Originator

Curator's Comment: Was launched in 1971

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q704S8
Gene ID: 311849.0
Gene Symbol: Crat
Target Organism: Rattus norvegicus (Rat)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Cholexamin

Approved Use

INDICATIONS: Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome

Launch Date

1970
Primary
Cholexamin

Approved Use

INDICATIONS: Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome

Launch Date

1969
Primary
Cholexamin

Approved Use

Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome

Launch Date

1970
PubMed

PubMed

TitleDatePubMed
Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart.
1976 May 26-29
Effect of nicomol on HDL cholesterol level.
1979 Aug
Effect of nicomol on high density lipoprotein (HDL) subfractions, HDL2e and HDL3e, separated by electrophoresis.
1981 Apr
Effects of some hypolipidemic drugs on biochemical values and on hepatic peroxisomal enzymes of normolipemic rat.
1981 Oct
Patents

Sample Use Guides

The usual adult dosage of this product for oral use is 200 to 400 mg of Nicomol three times daily after meals.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
NICOMOL
INN   MART.   MI   WHO-DD  
INN  
Official Name English
NICOMOL [MART.]
Common Name English
CHOLEXAMIN
Brand Name English
NICOMOL [MI]
Common Name English
Nicomol [WHO-DD]
Common Name English
nicomol [INN]
Common Name English
NICOMOL [JAN]
Common Name English
2-HYDROXY-1,1,3,3-CYCLOHEXANETETRAMETHANOL 1,1,3,3-TETRANICOTINATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98151
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
Code System Code Type Description
MESH
C008612
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
PUBCHEM
34081
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
NCI_THESAURUS
C84011
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
INN
2880
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID9048722
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103919
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
CAS
27959-26-8
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
EVMPD
SUB09240MIG
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
SMS_ID
100000084416
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
ECHA (EC/EINECS)
248-748-9
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
FDA UNII
215U8X2R44
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
DRUG CENTRAL
1917
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY
MERCK INDEX
m844
Created by admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
PRIMARY Merck Index